Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Location status: Recruiting
Location contact
Clinical Trials Referral Office
CONTACT
Evelyn A. Reynolds, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07062016
This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results and medical record databank for future studies.
Interested in participating?
Request Info18 year and older
Female
Observational
Rochester, Minnesota, 55905, United States
Location status: Recruiting
Clinical Trials Referral Office
CONTACT
Evelyn A. Reynolds, MD
PRINCIPAL_INVESTIGATOR
PRIMARY OBJECTIVE:
I. To generate preliminary data for a risk stratification model for recurrence including traditional histopathologic risk factors, molecular characterization in endometrial cancer patients with features of aggressive disease.
OUTLINE: This is an observational study.
Patients undergo blood and tissue sample collection and have their medical records reviewed throughout the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Non-interventional study
Time frame: Up to 3 years
Defined as time from primary staging surgery to recurrence or death.
Time frame: Up to 3 years
For each participant, a surgical tissue sample (OncoExtra) and a presurgical blood sample (RiskGuard) sample will be utilized to determine the presence of somatic and germline pathogenic variants. The count and percentage of patients with the presence of somatic or germline variants will be reported by The Cancer Genome Atlas (TGCA) class. The number, type, and function of somatic variants will also be reported by TGCA class. For genes with alterations seen in at least 10 patients, a log rank test will be used to assess whether RFS differs with respect to whether an alternation is present or not.
Contact information is provided by the study sponsor or research team.
Mayo Clinic
Other
MC230601 Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05691010
Endometrial Cancer, Endometrial Carcinoma
Basking Ridge, New Jersey, United States
View Trial DetailsNCT05256225
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Birmingham, Alabama, United States
View Trial DetailsNCT05919264
Adamantinomatous Craniopharyngioma, Adenocarcinoma
Phoenix, Arizona, United States
View Trial DetailsNCT07527143
Endometrial Carcinoma, Endometrial Neoplasms
Rochester, Minnesota, United States
View Trial Details